IP Library › Granted Patent US 12,559,536
Granted Patent B2
US 12,559,536 · App. 18/462,207 · Granted Feb 24, 2026

CD33 specific chimeric antigen receptors

Inventors: Rutul Shah (Germantown, MD); Tim Chan (Germantown, MD); Peter Emtage (Germantown, MD); Ramya Yarlagadda (Germantown, MD)
Assignee: PRECIGEN, INC.
C07K14/70503A61K40/11A61K40/15A61K40/31A61K40/4205A61K40/4211A61K40/4224C07K14/7051C07K14/70517C07K14/70521C07K14/70575C07K14/70578C07K14/70596C07K14/71C07K16/2803C12N5/0636A61K2039/505A61K2039/57A61K2239/29A61K2239/31A61K2239/38A61K2239/48C07K2317/24C07K2317/622C07K2317/73C07K2319/00C07K2319/02C07K2319/03C12N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,559,536
App. No.
18/462,207
Granted
Feb 24, 2026
Kind
B2
Abstract

Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from a CD33 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders such as acute myeloid leukemia (AML), and relapsed or refractory AML.

Claims (19)

1 . A vector comprising a backbone and a nucleic acid sequence encoding:

(a) a polypeptide having the amino acid sequence of SEQ ID NO: 36 or 56; and

(b) a chimeric antigen receptor (CAR) comprising a CD33 antigen-binding domain, a transmembrane domain, and an intracellular signaling domain; wherein the CD33 antigen binding domain comprises either:

(i) a polypeptide having the amino acid sequence of SEQ ID NO: 1 and a polypeptide having the amino acid sequence of SEQ ID NO: 3;

(ii) a polypeptide having the amino acid sequence of SEQ ID NO: 9 and a polypeptide having the amino acid sequence of SEQ ID NO: 10;

(iii) a polypeptide having the amino acid sequence of SEQ ID NO: 11 and a polypeptide having the amino acid sequence of SEQ ID NO: 12; or

(iv) a polypeptide having the amino acid sequence of SEQ ID NO: 13 and a polypeptide having the amino acid sequence of SEQ ID NO: 14.

2 . The vector of claim 1 , wherein the vector is a lentivirus vector, a retroviral vector, or a non-viral vector.

3 . The vector of claim 1 , further comprising an hEF1a1 promoter.

4 . The vector of claim 1 , wherein:

the CAR further comprises a stalk domain comprising a polypeptide having at least 90% identity to the amino acid sequence of SEQ ID NO: 22; and

the intracellular signaling domain comprises: (i) a costimulatory signaling domain comprising a polypeptide having at least 90% identity to the amino acid sequence of SEQ ID NO: 24 or 28; and (ii) a CD3 zeta signaling domain comprising a polypeptide having at least 90% identity to the amino acid sequence of SEQ ID NO: 26.

5 . An immune effector cell comprising the vector of claim 1 .

6 . The immune effector cell of claim 5 , wherein the cell is a T cell, a Natural Killer (NK) cell, a cytotoxic T lymphocyte (CTL), or a regulatory T cell.

7 . A composition comprising the vector of claim 1 .

8 . A kit comprising the vector of claim 1 .

9 . The vector of claim 1 , wherein the nucleic acid encodes a polypeptide having the amino acid sequence of SEQ ID NO: 56.

10 . The vector of claim 1 , wherein the CD33 antigen binding domain comprises: (1) a polypeptide having the amino acid sequence of SEQ ID NO: 1; and (ii) a polypeptide having the amino acid sequence of SEQ ID NO: 3.

11 . The vector of claim 1 , wherein the CD33 antigen binding domain comprises a polypeptide having the amino acid sequence of SEQ ID NO: 8.

Assignments (1)
PATENT SECURITY AGREEMENT Recorded Sep 3, 2025
From: PRECIGEN, INC.; GENVEC LLC; PRECIGEN ACTOBIO, INC.; EXEMPLAR GENETICS, LLC
To: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
Reel/Frame 072828/0564 →
Continuity (3)
Continuation 15616869 · Jun 7, 2017
Provisional Application 62347503 · Jun 8, 2016
Related Publication 20240254188A1 · Aug 1, 2024
References Cited (66)
US 5693761A · Queen et al. · 1997 [cited by applicant]
US 5714350A · Co et al. · 1998 [cited by applicant]
US 6007814A · Scheinberg · 1999 [cited by applicant]
US 7119183B2 · Seed · 2006 [cited by examiner]
US 7985559B2 · Freeman et al. · 2011 [cited by applicant]
US 8790649B2 · Setlady et al. · 2014 [cited by applicant]
US 8802374B2 · Jensen · 2014 [cited by applicant]
US 9447194B2 · Jensen · 2016 [cited by applicant]
US 9580685B2 · Jensen · 2017 [cited by applicant]
US 10570186B2 · Cooper et al. · 2020 [cited by applicant]
US 10676717B2 · Brown et al. · 2020 [cited by applicant]
US 20090123944A1 · Finney et al. · 2009 [cited by applicant]
US 20160096892A1 · Brogdon et al. · 2016 [cited by applicant]
US 20160355590A1 · Epstein · 2016 [cited by examiner]
EP 0566647B1 · 2003 [cited by applicant]
WO 2012079000A1 · 2012 [cited by applicant]
WO 2014186469A2 · 2014 [cited by applicant]
WO 2015089344A1 · 2015 [cited by applicant]
WO 2015105522A1 · 2015 [cited by applicant]
WO 2015123642A1 · 2015 [cited by applicant]
WO 2015142675A2 · 2015 [cited by applicant]
WO 2015150526A2 · 2015 [cited by applicant]
WO 2015157391A1 · 2015 [cited by applicant]
WO 2015179801A1 · 2015 [cited by applicant]
WO 2016014576A1 · 2016 [cited by applicant]
WO 2016120216A1 · 2016 [cited by applicant]
WO 2016201304A1 · 2016 [cited by applicant]
WO 2017214333A1 · 2017 [cited by applicant]
Vogler et al, Molecular Therapy, vol. 18, No. 7, Jul. 2010. (Year: 2010). [cited by examiner]
Rudikoff et al, PNAS USA 79: 1979-1983 (1982). (Year: 1982). [cited by examiner]
Ng et al., Genome Research, 11:863-874 (2001). [cited by applicant]
Jonson et al., Protein Engineering, 14:397-402 (2001). [cited by applicant]
Bendig, Methods: A Companion to Methods in Enzymology , 8:83-93 (1995). [cited by applicant]
Kussie et al., Journal of Immunology, 152:146-152 (1994). [cited by applicant]
Chen et al, EMBO J., 14:2784-2794 (1995). [cited by applicant]
Jones et al., Front.Pharmacol., 5:254 (2014). [cited by applicant]
Hudecek et al., Blood, 118:643 (2011). [cited by applicant]
Wang et al., Blood, 122:4491 (2013). [cited by applicant]
Chan et al., “CD19-specific chimeric antigen receptor-modified T cells with safety switch produced under ‘Point-of-Care’ using the Sleeping Beauty system for the very rapid manufacture and treatment of B-cell malignanci… [cited by applicant]
Song et al., “Autologous T Cells Modified to Co-express CD33-Specific Chimeric Antigen Receptor and a Kill Switch for Treatment of CD33+ Acute Myeloid Leukemia,” 59th American Society of Hematology (ASH) Annual Meeting … [cited by applicant]
Song et al., “Chimeric Antigen Receptor-Modified T cells for the Treatment of Acute Myeloid Leukemia Expressing CD33,” American Society of Hematology 58th Annual Meeting (ASH), Poster, Dec. 5, 2016. [cited by applicant]
Dutour etal, Advances in Hematology, 2012, 10 pages. [cited by applicant]
Pizzitola et al., Leukemia, 28:1596-1605 (2014). [cited by applicant]
Figueroa et al. Chimeric Antigen Receptor Engineering: A Right Step in the Evolution of Adoptive Cellular Immunotherapy. International Reviews of immunology. 2015. 154-187. [cited by applicant]
International Search Report and Written Opinion dated Nov. 7, 2017 for International PCT Patent Application No. PCT/US2017/036440. [cited by applicant]
Ruella et al. Smart CARS: optimized development of a chimeric antigen receptor (CAR) T cell targeting epidermal growth factor receptor variant III (EGFRvIII) for glioblastoma. Ann Transl Med 4(1):13 (2016). [cited by applicant]
Paszkiewicz, Paulina Joanna. Development of a truncated EGFR marker as a safeguard for adoptive T cell therapy. Ph.D. Thesis Paper. 2014. 192 pages. [cited by applicant]
Jonnalagadda, et al., “Efficient selection of genetically modified human T cells using methotrexate-resistant human dihydrofolate reductase”, Gene Therapy (2013) 20, 853-860. [cited by applicant]
Jonnalagadda, et al., “Engineering Human T Cells for Resistance to Methotrexate and Mycophenolate Mofetil as an In Vivo Cell Selection Strategy”, PLOS One, Jun. 2013, vol. 8, Issue 6 pp. 1-10. [cited by applicant]
Paskiewicz, et al., “Targeted antibody-mediated depletion of murine CD19 Cart cells permanently reverses B cell aplasia”, J Clin Invest (2016); 126(11):4262-4272. [cited by applicant]
Wang, et al. “A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells”, Gene Therapy, Blood, Aug. 4, 2011, vol. 118, No. 5. [cited by applicant]
Huang, et al. Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies. Mol Ther. Mar. 2008;16(3):580-9. [cited by applicant]
O'Hear, et al. Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia. Haematologica. Mar. 2015; 100(3):336-44. doi: 10.3324/haematol.2014.1127 48. [cited by applicant]
D.A. Einfeld et al., Molecular Cloning of the Human B Cell CD20 Receptor Predicts a Hydrophobic Protein with Multiple Transmembrane Domains, 7 EMBO J. 711 (1988). [cited by applicant]
Mascha Binder et al., The Epitope Recognized by Rituximab, 108 Blood 1975 (2006). [cited by applicant]
Jianzhi Zhang, Rates of Conservative and Radical Nonsynonymous Nucleotide Substitutions in Mammalian Nuclear Genes, 50 J. Mol. Evol. 56 (2000). [cited by applicant]
Pauline C. Ng & Steven Henikoff, Predicting Deleterious Amino Acid Substitutions, 11 Genome Res. 863 (2001). [cited by applicant]
Arvind Rajpal et al., A General Method for Greatly Improving the Affinity of Antibodies by Using Combinatorial Libraries, 102 Proc. Nat'l Acad. Sci. U.S. 8466 (2005). [cited by applicant]
Inbal Sela-Culang et al., The Structural Basis of Antibody-Antigen Recognition, 4 Front. Immunol. 302 (2013). [cited by applicant]
Kevin C. Entzminger et al., De Novo Design of Antibody Complementarity Determining Regions Binding a Flag Tetrapeptide, 7 Sci. Rep. 10295 (2017). [cited by applicant]
Julie P. Deans et al., CD20-Mediated Apoptosis: Signalling Through Lipid Rafts, 107 Immunology 176 (2002). [cited by applicant]
Martin McLaughlin & Koen Vandenbroeck, The Endoplasmic Reticulum Protein Folding Factory and its Chaperones: New Targets for Drug Discovery?, 162 Brit. J. Pharmacol. 328 (2011). [cited by applicant]
Ziqing Liu et al., Systematic Comparison of 2A Peptides for Cloning Multi-Genes in a Polycistronic Vector, 7 Sci. Rep. 2193 (2017). [cited by applicant]
Ekaterina Minskaia & Martin D. Ryan, Protein Coexpression Using FMDV 2A: Effect of “Linker” Residues, 2013 Biomed Res. Int., (2013). [cited by applicant]
Garry A. Luke, Translating 2A Research into Practice, in Innovations in Biotechnology 162 (M. Tank ed., InTech 2012). [cited by applicant]
Hiroyuki Mizuguchi et al., IRES-Dependent Second Gene Expression is Significantly Lower Than Cap-Dependent First Gene Expression in a Bicistronic Vector, 1 Mol. Therapy 376 (Apr. 2000). [cited by applicant]